Literature DB >> 10613998

Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

F H Jafary1, C D Kimmelstiel.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10613998     DOI： 10.1023/a:1018775015882

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  63 in total

1.  The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.

Authors:  L Schwartz; J Lesperance; M G Bourassa; C Eastwood; F Kazim; M Arafah; L Ganassin
Journal:  Am Heart J       Date:  1990-02       Impact factor: 4.749

2.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

3.  Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.

Authors:  J P Zidar
Journal:  Am J Cardiol       Date:  1998-09-10       Impact factor: 2.778

4.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

5.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

6.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

7.  Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia.

Authors:  J G Kelton; D Sheridan; H Brain; P J Powers; A G Turpie; C J Carter
Journal:  J Lab Clin Med       Date:  1984-04

8.  Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes.

Authors:  R R Azar; R G McKay; P D Thompson; J A Hirst; J F Mitchell; D B Fram; D D Waters; F J Kiernan
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

9.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

10.  Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.

Authors:  F V Aguirre; E J Topol; J J Ferguson; K Anderson; J C Blankenship; R R Heuser; K Sigmon; M Taylor; R Gottlieb; G Hanovich
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690
View more
  1 in total

1.  Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.

Authors:  C Kimmelstiel; R Phang; A Rehman; W Rand; R Miele; J Rhofiry; D A MacIsaac; W Gouveia; D Denier; R C Becker
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.